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Abstract
Background: Although several studies have found probiotics encouraging in prevention of gestational diabetes
mellitus (GDM), the evidence for the use of probiotics in diagnosed GDM is largely limited. The aim of this study
was to assess the effect of a probiotic supplement capsule containing four bacterial strains on glucose metabolism
indices and weight changes in women with newly diagnosed GDM.
Methods: Sixty-four pregnant women with GDM were enrolled into a double-blind placebo-controlled randomized
clinical trial. They were randomly assigned to receive either a probiotic or placebo capsule along with dietary
advice for eight consecutive weeks. The trend of weight gain along with glucose metabolism indices was assayed.
Results: During the first 6 weeks of the study, the weight gain trend was similar between the groups. However, in
the last 2 weeks of the study, the weight gain in the probiotic group was significantly lower than in the placebo
group (p < 0.05). Fasting blood sugar (FBS) decreased in both intervention (from 103.7 to 88.4 mg/dl) and control
(from 100.9 to 93.6 mg/dl) groups significantly, and the decrease in the probiotic group was significantly higher
than in the placebo group (p < 0.05). Insulin resistance index in the probiotic group had 6.74 % reduction over the
study period (p < 0.05). In the placebo group, however, there was an increase in insulin resistance index (6.45 %),
but the observed change in insulin resistance was not statistically significant. Insulin sensitivity index was increased
in both groups. The post-intervention insulin sensitivity index in the probiotic group was not significantly different
from placebo when adjusted for the baseline levels.
Conclusions: The probiotic supplement appeared to affect glucose metabolism and weight gain among pregnant
women with GDM. This needs to be confirmed in other settings before a therapeutic value could be approved.
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Background
Gestational diabetes mellitus (GDM) is a condition in
which the pregnant woman has high serum glucose
levels during the gestation. It is defined as carbohydrate
intolerance first diagnosed during pregnancy [1]. It is
characterized by maternal insulin resistance and is asso-
ciated with inflammation through the gestation [2].
GDM is shown to be associated with a range of adverse
pregnancy outcomes such as preeclampsia and abnormal
delivery. The newborns may also suffer from some
health problems as a consequence. GDM rates are in-
creasing both in high-income as well as the low- and
middle-income countries as a consequence of increasing
rates of overweight and obesity [3]. Both women with
GDM and their infants are at increased risk of diabetes
mellitus and metabolic dysfunction later in life [4, 5]. It
has been confirmed that treatment of GDM improves
pregnancy outcomes with significant reductions in the
rate of serious perinatal problems such as macrosomia,
dystocia and inevitable caesarean section deliveries.
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Generally, the treatment includes diet with or without
medication [6].
Probiotics are known to be the good bacteria usually
consumed as capsules or drinks to supplement the bowl
bacteria. As narrated by Salmin, currently, the most
commonly used definition for probiotics is given by
Fuller as “Probiotics are live microbial feed supplements
which beneficially affect the host animal by improving
its intestinal microbial balance” [7, 8]. They are shown
to affect the consumer’s metabolism. The use of probio-
tics has been investigated on various infectious or nonin-
fectious conditions [9–13]. Probiotics have also been
investigated for their effect on type 2 diabetes or preven-
tion of gestational diabetes [14–21]. Although several
studies have found probiotics encouraging in prevention
of GDM, the evidence for use of probiotics for those
with diagnosed GDM is largely limited. The aim of this
study was to assess the effect of a probiotic supplement
capsule containing four bacterial strains in comparison
with placebo on glucose metabolism indices and weight
changes in women with newly diagnosed GDM.
Methods
In a double-blind placebo-controlled randomized clinical
trial, 64 subjects with GDM referred to Alzahra Univer-
sity Hospital in Tabriz, Northwest of Iran, were enrolled
during the spring and summer months in 2014. The pa-
tients were randomly allocated to receive either pro-
biotic supplement or placebo capsules once daily for
8 weeks.
Each probiotic capsule of four bacterial strains (4 bio-
cap > 4 × 109CFU) in standard freeze-dried culture in-
cluded Lactobacillus acidophilus LA-5, Bifidobacterium
BB-12, Streptococcus thermophilus STY-31 and Lactoba-
cillus delbrueckii bulgaricus LBY-27 plus dextrose an-
hydrous filler and magnesium stearate lubricant
produced by CHR HANSEN, Denmark, packed and gel-
atin covered in Tehran Darou drug industries.
The eligible subjects to be enrolled included all nul-
liparous women with GDM screened during 24–28 weeks
of gestation who were referred to the specialty and sub-
specialty gynaecology or endocrinology clinics of Tabriz
University of Medical Sciences.
The inclusion criteria were as follows: Nulliparity; Ges-
tational diabetes between 24 and 28 week (+6 days) of
gestation newly diagnosed through screening done by ei-
ther a gynaecologist or an internal medicine specialist;
Age range of 18–45 years; Fasting blood sugar range of
92 to 126 mg/dl early at the diagnosis; Body mass index
(BMI) above 18.5 kg/m2; No history of type 2 diabetes
mellitus; No history of chronic diseases; No smoking
and alcohol consumption; Not using probiotic food
products during the 2 weeks before intervention; Not
using antibiotics during the month before intervention;
Lack of acute gastrointestinal problems a month before
trial and Not using Glucocorticoids (GCs) and immuno-
suppressive drugs. The exclusion criteria were the fol-
lowing: Needing to use insulin of other diabetes drugs
through the study period; Use of antibiotics through the
study period and Use of GCs and immunosuppressive
drugs through the study period.
At baseline, the purpose and method of study were de-
scribed in detail for the patients, and a trained practi-
tioner provided similar diet recommendations for
patients in both groups. Written informed consent was
obtained from all the patients for being enrolled into this
study. Then, during an interview with the participants, a
general questionnaire and a dietary recall questionnaire
were completed. The general questionnaire was used to
collect data on demographic information, weight before
pregnancy, physical activity, past medical history, drug
history over the past month and use of probiotic food
products over the past 2 weeks before the study. Physical
activity was only measured at baseline. Subjects were
categorized into three groups: those with low physical
activity (those with a sedentary life and physical activity
limited to chores such as cooking, sewing, working with
computer and so on); those with moderate physical ac-
tivity whose activity is limited to works such as cleaning
or taking care of children and other works needing small
amounts of movement or bodily movements and those
with high physical activity who used to have brisk walk-
ing, running, biking and swimming regularly [22]. A 24-
h dietary recall questionnaire was completed at sessions
of three nonconsecutive days each (two weekdays and
one in weekend) once at the baseline, and then after
4 weeks and also at the end of study. To obtain the nu-
trient intake of participants based on these 3-day food
diaries, we used Nutritionist IV software (First Databank,
San Bruno, Calif., USA) modified for Iranian foods.
Weight, height and blood pressure were measured, and
some information about their dietary habits and weight
before pregnancy were also taken. Seca 206 wall-
mounted stadiometer and Seca 813 digital scale were
used to measure weight and height. Body mass index
(BMI) was then calculated and categorized according to
the world health organization guidelines [23].
After taking blood samples and randomly allocating
them into one of two study groups, subjects were given
a 2-week package of either probiotic or placebo capsules.
Fasting blood samples (10 ml) before and after the inter-
vention were collected from forearm vein by a laboratory
technician for measurement of fasting blood glucose and
fasting insulin at Alzahra Hospital laboratory. Plasma
glucose levels were assessed using a glucose oxidase/per-
oxidase method as an enzymatic colorimetric (GOD-
PAP) methodology [24] by Pars Azmoon test kits (Pars
Azmoon Inc, Tehran, Iran). Serum insulin levels were
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measured by ELISA method using Monobind kit [25].
Homeostasis model assessment insulin resistance
(HOMA-IR) was used to assess insulin resistance [26]. A
HOMA-IR value above 3.8 is defined as insulin resist-
ance [27]. QUICKI index (quantitative insulin sensitivity
check) was used in present study to assess insulin sensi-
tivity [28]. Details of data collection methodology and la-
boratory testing are published in the trial protocol
elsewhere [29].
HOMA-IR was used as the main outcome for estimat-
ing the sample size. Sample size was estimated using pa-
rameters from the study by Asemi et al. assuming a
maximum type 1 error of 0.05 and 90 % statistical
power, HOMA-IR index standard deviation equal to
31 % and an effect size equal to 0.2; a total number of
32 subjects were estimated to be enrolled for each group
taking into account 10 % attrition rate [30]. A total of 64
pregnant women with GDM were randomly allocated
using block randomization techniques stratified accord-
ing to the prepregnancy fasting blood sugar (FBS) and
BMI groups. To ensure double blinding, a coder an-
onymously labelled the capsules packages as “A” or “B”
and therapist assigned them according to the random se-
quence generated through a computer program [31]. Pa-
tients were visited in obstetrics and gynaecology clinics
of Alzahra University Hospital in Tabriz. Weight and
blood pressure measurements were also done every
2 weeks. Through the study course, in order to improve
the compliance, the participants were contacted by tele-
phone each week asked about any problems they may
have and about gastrointestinal symptoms as well as use
of any drugs through the period.
Fig. 1 CONSORT 2010 flow diagram for the randomized placebo-controlled clinical trial for the effect of probiotics on gestational diabetes
mellitus (GDM)
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Data were analyzed using SPSS statistical software
package version 22. Mean response scales measured over
the 8-week study period were analyzed using appropriate
statistical methods including independent samples t test,
repeated measurements analysis of variance, one-way
analysis of variance and analysis of covariance. Energy-
adjusted nutrient intakes were calculated as the residuals
from the regression model, with absolute nutrient intake
as the dependent variable and total energy intake as the
independent variable. A p value below 0.05 was consid-
ered as statistically significant.
Results
A total of 64 nulliparous pregnant women with gesta-
tional diabetes participated in the study, data from the
29 patients in the probiotic group and 27 in the placebo
group were finally analyzed (see CONSORT flow dia-
gram in Fig. 1). Mean age of the patients was 27.3 (SD:
5.8) years. Comparison of the baseline characteristics for
both groups of pregnant women under study are pre-
sented in Table 1.
Comparing the frequency of blood glucose levels at
baseline in pregnant women showed that in probiotic
group, 69 % of mothers had fasting plasma sugar be-
tween 92 and 104 mg/dl and among 31 % of them, FBS
ranged 105–126 mg/dl. The values in the placebo group
were 66.7 and 33.3 %, respectively. There was no statisti-
cally significant difference between the groups in terms
of classification of blood glucose at baseline. Mean
weight change over the study period is compared be-
tween the groups in Fig. 2.
The weight gain over the study period, adjusted also
for energy intake, is given in Table 2. It shows that no
significant differences between the intervention and con-
trol groups were observed in weight gain measures
among the pregnant women within 2-week intervals
during the first 6 weeks of the study. However, in the
last 2 weeks of the study, the weight gain in pregnant
women in the probiotic group was significantly lower
than in the placebo group. The results stayed statistically
significant after adjusting for the changes in daily energy
intake between the two groups, (p < 0.05).
Fasting blood sugar levels, fasting insulin level, insulin
resistance index (HOMA-IR) and insulin sensitivity
index (QUICKI index) were not found to be different be-
tween the probiotic supplement and placebo groups at
baseline. According to the results of the analysis of co-
variance, FBS in both the intervention and control
groups decreased significantly (14.66 and 7.38 %, re-
spectively), both of which were statistically significant (p
< 0.05). Post-intervention comparison, after adjustment
for baseline values, showed that decrease in the pro-
biotic group was significantly higher than in the placebo
group (p < 0.05). Insulin resistance index in the probiotic
group significantly decreased over the study period
(6.74 % reduction), which was statistically significant (p
< 0.05). In the placebo group, however, there was an in-
crease in insulin resistance (6.45 %), but the change was
not statistically significant. Insulin sensitivity index was
increased in both groups. These changes in the probiotic
group (5.76 %) were statistically significant. The post-
intervention insulin sensitivity index in the probiotic
group was not significantly different from that in the
placebo group when adjusted for the baseline levels. De-
tailed information on changes in glucose metabolism in-
dices are provided in Table 3.
Discussion
It was observed in present study that the weight gain did
not change during the first 6 weeks of the study, but, in
the last 2 weeks of the study, the weight gain in pregnant
women in the probiotic group was significantly lower
than in the placebo group. With respect to glucose me-
tabolism indices, probiotic supplementation was also
Table 1 Baseline comparison of demographic and
anthropometric characteristics of the pregnant women with
gestational diabetes mellitus enrolled either to receive probiotic
or placebo
Baseline measures Intervention Placebo p value
(N = 29) (N = 27)
Maternal age 28.14 ± 6.24 26.48 ± 5.23 0.36
Family history of DM
Yes 16 (55.2 %) 12 (44.4 %) 0.59
No 13 (44.8 %) 15 (55.6 %)
Educational level
Under graduate diploma 4 (13.8 %) 5 (18.5 %) 0.91
High school diploma 17 (58.6 %) 15 (55.6 %)
Academic education 8 (27.8 %) 7 (25.9 %)
Employment
Employed 10 (34.5 %) 9 (33.3 %) 1.00
Unemployed or housewife 19 (65.5 %) 18 (66.7 %)
Residence
Urban
Rural 17 (58.6 %) 15 (55.6 %) 1.00
12 (41.4 %) 12 (44.4 %)
Physical activity
Low 22 (75.9 %) 17 (63.0 %)
Moderate 7 (24.1 %) 10 (37.0 %) 0.38
High 0 0
Weight (kg) 83.27 ± 12.06 78.67 ± 11.09 0.14
Height (cm) 162.68 ± 5.65 162.14 ± 5.93 0.72
Body mass index (kg/m2) 31.41 ± 3.92 29.86 ± 3.39 0.12
Numeric scales are reported as mean ± standard deviation, and categorical
measures are reported as frequency (percent)
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effective. FBS decreased in the probiotic group signifi-
cantly more than in the placebo group. Insulin resistance
index in the probiotic group significantly decreased over
the study period (6.74 % reduction), which was statisti-
cally significant while the increase in insulin resistance
(6.45 %) in the placebo group was not statistically signifi-
cant. Insulin sensitivity index was increased in both
groups, but the post-intervention insulin sensitivity
index in the probiotic group was not significantly differ-
ent from the placebo group.
Although several studies have been done on effect of
probiotics on preventing GDM and some studies have
been done on general glucose patterns among normal
pregnant populations, studies are scarce investigating
the effect of probiotics when taken after diagnosis of
GDM. One very recent double-blind randomized clinical
trial on women with a new diagnosis of GDM and im-
paired glucose tolerance assigned them to a daily pro-
biotic (Lactobacillus salivarius UCC118) or placebo
capsule. Among the 149 women enrolled, no difference
Fig. 2 Mean weight change of women with gestational diabetes mellitus (GDM) over the 8-week study period compared between the probiotic
and placebo groups
Table 2 Weight gain trend over the 8-week study period comparing women gestational diabetes mellitus receiving probiotic
supplement versus placebo capsules
Weight gain Probiotic (n = 29) Placebo (n = 27) Mean difference (95 % CI) p value* p value**
First 2 weeks (mean ± SE) 0.83 ± 0.08 0.89 ± 0.07 −0.61 (−0.29,0.17) 0.59 0.34
Second 2 weeks (mean ± SE) 0.98 ± 0.07 0.93 ± 0.06 0.05 (−0.14,0.25) 0.60 0.69
Third 2 weeks (mean ± SE) 0.91 ± 0.06 1.00 ± 0.05 −0.09 (−0.27,0.08) 0.31 0.19
Fourth 2 weeks (mean ± SE) 0.74 ± 0.14 1.22 ± 0.11 −0.48 (−0.85,−0.10) 0.01 0.02
First 4 weeks (mean ± SE) 1.82 ± 0.12 1.82 ± 0.12 −0.008 (−0.37,0.35) 0.96 0.62
Second 4 weeks (mean ± SE) 1.65 ± 0.13 2.22 ± 0.13 −0.57 (−0.95,−0.19) 0.004 0.004
* Independent samples t test
**One-way ANOVA with differences in energy intake as covariate
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was observed between the probiotic and placebo groups
in post-intervention fasting glucose levels. However, they
found a likely effect for the probiotic on lipid profile of
the patients [32]. Regardless of the differences in study
design and population, the main characteristic possibly
describing the reason for positive results in present
study may be attributed to different probiotic contents
of the supplement in two studies. Observing the effect of
probiotics in present study with a smaller sample size
while yielding reasonably narrower confidence interval
justifies a promising effect for the intervention used in
our study. Aside from the different probiotic in present
study and the magnitude of potential random error at-
tributable to the sample size, other issues may affect the
results either such as the variations in normal weight
gain through the pregnancy, variations in gut flora, phys-
ical activity and diet. Normally, such variations are con-
trolled through randomization, but this cannot be fully
guaranteed unless the study is large enough to ensure
the efficacy of randomization [33]. No doubt physical
activity is a major risk indicator in several noncommu-
nicable diseases including diabetes. In present study, the
physical activity was measured only at baseline, and we
recommend to consider it as a time-dependent variable
in future clinical trial studies assessing the role of pro-
biotics on GDM. Studies like present study conducted
specifically on patients diagnosed with GDM are quite
rare; however, there are bunches of studies on role of
probiotics on prevention of GDM or its related preg-
nancy outcomes. Generally, the effect of probiotics in
prevention of GDM and poor pregnancy outcomes have
been shown to be promising [6, 20, 21, 34–39]. Probio-
tics have also been investigated when combined with
diet recommendations. In a study from Finland, 256
pregnant women were randomized early through the
gestation to receive nutrition counselling or not to re-
ceive it as controls; the group with dietary intervention
was further randomized to receive probiotics (Lactoba-
cillus rhamnosus GG and Bifidobacterium lactis Bb12;
diet/probiotics) or placebo (diet/placebo). It was found
Table 3 Changes in glucose metabolism indices among women with gestational diabetes receiving probiotic supplement versus
placebo
Glucose metabolism indices Probiotic (n = 29) Placebo (n = 27) p value (Independent samples t test) p value (ANCOVA)
Fasting blood sugar (mg/dl)
Before trial 103.65 (1.34) 100.89 (1.52) 0.17 0.02
After trial 88.37 (2.05) 93.59 (3.61) 0.20
P (paired samples t test) <0.001 0.02
Absolute change −15.27 (1.83) −7.30 (3.04) 0.02
Relative change −14.66 (1.77) −7.38 (15.09) 0.03
Fasting serum insulin (μIU/ml)
Before trial 5.95 (0.50) 5.60 (0.37) 0.58 0.09
After trial 5.15 (0.41) 6.12 (0.50) 0.14
P (paired samples t test) 0.16 0.30
Absolute difference −0.80 (0.56) 0.52 (0.49) 0.08
Relative difference 10.55 (18.55) 14.55 (9.21) 0.85
HOMA-IR index
Before trial 1.52 (0.12) 1.38 (0.08) 0.41 0.03
After trial 1.11 (0.09) 1.40 (0.11) 0.06
P (paired samples t test) 0.007 0.93
Absolute difference −0.40 (0.13) 0.01 (0.12) 0.03
Relative difference −6.74 (14.84) 6.45 (9.22) 0.46
QUICKI index
Before trial 0.15 (0.00) 0.15 (0.00) 0.92 0.11
After trial 0.16 (0.00) 0.16 (0.00) 0.11
P (paired samples t test) 0.02 0.46
Absolute difference 0.008 (0.003) 0.002 (0.002) 0.16
Relative difference 5.76 (2.16) 1.38 (1.69) 0.12
HOMA-IR homeostasis model assessment insulin resistance, QUICKI quantitative insulin sensitivity check
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that blood glucose levels as well as HOMA-IR and
QUICKI indices were lowest in the diet/probiotics group
concluding that improved blood glucose control could be
reached by dietary counselling combined with probiotics
even in normoglycaemic pregnant women [40]. A recent
review on dietary interventions, lifestyle changes and diet-
ary supplements in preventing GDM has concluded that
trials in which only intake or expenditure has been the tar-
get of interventions may not achieve positive efficacy re-
sults, whereas combined interventions and dietary and
lifestyle interventions could show better efficacy in the re-
duction of GDM prevalence. The same review has stated
the results of probiotic studies to be promising and has
recommended future larger scale studies [41]. Although,
the cost-effectiveness of probiotics has not been well doc-
umented in literature, probiotic supplements have been
shown to have acceptability among patients [42, 43].
About 95 % of the intestinal microbiome in healthy
people with normal weight consists of the species be-
longing to three phyla of the bacteria including Bacteroi-
detes, Firmicutes and Actinobacteria. The plausibility of
the observed effect of probiotics is not much hard to be
approved considering the available evidence on role of
healthy gut microbiome on carbohydrate metabolism
and the synergistic relationships of probiotic foods and
supplements with the host gut microbiome [21, 44, 45].
To complete the plausibility pattern, the changes in gut
microbiome during diabetes mellitus should also be con-
sidered. A new theory suggests that gut microbiota have
a role in the regulation of the energy homeostasis and
causing metabolic diseases and insulin resistance [46]. It
has been shown that type 2 diabetes is associated with
changes in gut microbiome. For instance, it has been
shown that the ratio of Bacteroidetes to Firmicutes spe-
cies is associated with diabetes type 2 and FBS, especially
that the changes in gut microbiome are different from
what is observed during obesity and a larger number of
opportunistic pathogens along with a lower number of
butyrate-producing bacteria are attributed to presence of
diabetes [21, 47–51].
Conclusions
The probiotic supplement appeared to affect glucose
metabolism and weight gain among pregnant women
with GDM.
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